Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391334 | 1.00 | POLB (0.35) | POLBGAAHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL20787645 | 0.83 | POLB (0.35) | POLBGAAHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL29534779 | 0.80 | TSHR (0.33) | MAPTTSHR | |
| SCHEMBL27768847 | 0.80 | HSP90AA1 (0.38) | POLBGAAHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL1005974 | 0.79 | POLB (0.33) | POLBGAAHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL995991 | 0.79 | NPC1 (0.33) | KDM4EHPGDALDH1A1TSHR | |
| SCHEMBL29533582 | 0.79 | ROCK2 (0.31) | — | |
| SCHEMBL5573655 | 0.77 | STS (0.30) | — | |
| SCHEMBL4266302 | 0.77 | ALDH1A1 (0.41) | POLBMAPK1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2868301 | 0.77 | GAA (0.38) | POLBGAAHSP90AA1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 668 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-06-05 | — | — | US | claimed |
| CN-117264302-A | Styrene butadiene rubber material for inner rubber layer of wear-resistant sand-absorbing rubber tube | 蚌埠惠华管业有限公司 | 2023-12-22 | — | — | CN | claimed |
| WO-2022212752-A1 | DEGRADABLE COPOLYMERS OF ENOL ETHERS WITH OLEFINIC MONOMERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3634928-B1 | METHOD OF INCREASING ALPHA-OLEFIN CONTENT | LIQUIDPOWER SPECIALTY PRODUCTS INC (US) | 2021-04-21 | — | — | EP | claimed |
| US-10973847-B2 | Core-to-surface polymerization for the synthesis of star polymers and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-04-13 | — | — | US | claimed |
| US-20200377652-A1 | HIGH MOLECULAR WEIGHT POLYOXYALKYLENE WITH LOW GLASS TRANSITION TEMPERATURE, PRODUCED BY THE GRAFTING THROUGH METHOD | COVESTRO DEUTSCHLAND AG (DE) | 2020-12-03 | — | — | US | claimed |
| EP-1501784-B1 | INTEGRATED CHEMICAL PROCESSES FOR INDUSTRIAL UTILIZATION OF SEED OILS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-03-13 | — | — | EP | claimed |
| US-9328108-B2 | Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2016-05-03 | — | — | US | claimed |
| US-8981082-B2 | Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2015-03-17 | — | — | US | claimed |
| US-20140235852-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2014-08-21 | — | — | US | claimed |
| WO-2003011298-A1 | ANTIBACTERIAL OXAZINONES AND METHODS FOR THEIR USE AND SYNTHESIS | CHIROLOGIX PHARMACEUTICALS INC. (CA) | 2003-02-13 | — | — | WO | claimed |
| US-6476167-B2 | REACTION PRODUCT OF: A CYCLIC OLEFIN MONOMER, WITH A CHAIN TRANSFER AGENT, IN PRESENCE OF A POLYMERIZATION CATALYST, WHEREIN THE FUNCTIONALITY OF OLEFIN DEFINED BY VAPOR PHASE OSMOMETRY AND TITRATION RANGES FROM 1.7 TO 2.2 | BAYER CORPORATION | 2002-11-05 | — | — | US | claimed |
| EP-1161460-A4 | POLYOLEFIN COMPOSITIONS HAVING ENHANCED ULTRAVIOLET AND OXIDATIVE RESISTANCE AND METHODS FOR THEIR PRODUCTION AND USE | ADVANCED POLYMER TECHNOLOGIES (US) | 2002-04-17 | — | — | EP | claimed |
| EP-1088000-A4 | POLYOLEFIN COMPOSITIONS HAVING VARIABLE TOUGHNESS AND/OR HARDNESS | MATERIA INC (US) | 2002-03-06 | — | — | EP | claimed |
| EP-1161460-A1 | POLYOLEFIN COMPOSITIONS HAVING ENHANCED ULTRAVIOLET AND OXIDATIVE RESISTANCE AND METHODS FOR THEIR PRODUCTION AND USE | Advanced Polymer Technologies, Inc. (US) | 2001-12-12 | — | — | EP | claimed |
| US-6303837-B1 | CYCLOOLEFINATION BY METATHESIS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-16 | — | — | US | claimed |
| WO-2000046256-A9 | POLYOLEFIN COMPOSITIONS HAVING ENHANCED ULTRAVIOLET AND OXIDATIVE RESISTANCE AND METHODS FOR THEIR PRODUCTION AND USE | ADVANCED POLYMER TECHNOLOGIES (US) | 2001-09-27 | — | — | WO | claimed |
| EP-1088000-A1 | POLYOLEFIN COMPOSITIONS HAVING VARIABLE TOUGHNESS AND/OR HARDNESS | Materia, Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-2000046256-A1 | POLYOLEFIN COMPOSITIONS HAVING ENHANCED ULTRAVIOLET AND OXIDATIVE RESISTANCE AND METHODS FOR THEIR PRODUCTION AND USE | ADVANCED POLYMER TECHNOLOGIES, INC. (US) | 2000-08-10 | — | — | WO | claimed |
| WO-1999060030-A1 | POLYOLEFIN COMPOSITIONS HAVING VARIABLE TOUGHNESS AND/OR HARDNESS | MATERIA, INC. (US) | 1999-11-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973847-B2 | Core-to-surface polymerization for the synthesis of star polymers and uses thereof | STARD7, MB, STARD3 | POLB 1236/4885GAA 1708/4885HSP90AA1 3634/4885 |
| US-20140235852-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | CTRC, GTF3C4, CTSC | POLB 1281/4885GAA 457/4885HSP90AA1 2734/4885 |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | POLB 3594/4885GAA 1503/4885HSP90AA1 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.